Nothing Special   »   [go: up one dir, main page]

CO5570674A2 - Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos - Google Patents

Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos

Info

Publication number
CO5570674A2
CO5570674A2 CO04034582A CO04034582A CO5570674A2 CO 5570674 A2 CO5570674 A2 CO 5570674A2 CO 04034582 A CO04034582 A CO 04034582A CO 04034582 A CO04034582 A CO 04034582A CO 5570674 A2 CO5570674 A2 CO 5570674A2
Authority
CO
Colombia
Prior art keywords
hidroxifenil
pirrolidone
alcoxi
pde
inhibitors
Prior art date
Application number
CO04034582A
Other languages
English (en)
Inventor
Liu Ruiping
Vivo Michael De
Hans-Jurgen Ernst Hess
Allen Hopper
Erik Kuester
Tehim Ashok
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of CO5570674A2 publication Critical patent/CO5570674A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

1.- Un compuesto de Fórmula I: donde X es O;R1 es alquilo con entre 1 y 8 átomos de carbono donde optativamente uno o más grupos -CH2CH2- se reemplazan en cada caso con grupos -CH=CH- o - C=C-,alquilo con entre 1 y 8 átomos de carbono que está sustituido una o más veces por halógeno, oxo o combinaciones de los mismos donde optativamente uno o más grupos -CH2CH2- se reemplazan en cada caso con grupos -CH=CH- o -C=C-,cicloalquilo con entre 3 y 8 átomos de carbono, que no está sustituido o está sustituido una o más veces por halógeno, oxo, alquilo con entre 1 y 4 átomos de carbono o combinaciones de los mismos, un grupo heterocíclico, que es saturado, parcialmente saturado o totalmente insaturado, con entre 5 y 10 átomos en el anillo en donde al menos un átomo del anillo es un átomo de N, O o S que no está sustituido o está sustituido una o más veces por halógeno, arilo, alquilo, alcoxi, ciano, trifluorometilo, nitro, oxo, amino, alquilamino, dialquilamino, o combinaciones de los mismos,arilo con entre 6 y 14 átomos de carbono, que no está sustituido o está sustituido una o más veces por halógeno, CF3, OCF3, alquilo, hidroxi, alcoxi, nitro, metilendioxi, etilendioxi, amino, alquilamino, dialquilamino, hidroxialquilo, hidroxialcoxi, carboxi, ciano, acilo, alcoxicarbonilo, alquiltio, alquilsulfinilo, alquilsulfonilo, fenoxi, acilamido y aciloxi o combinaciones de los mismos, arilalquilo con entre 8 y 16 átomos de carbono, que está insustituido o sustituido una o más veces por halógeno, CF3, OCF3, alquilo, hidroxi, alcoxi, nitro, metilendioxi, etilendioxi, amino, alquilamino, dialquilamino, hidroxialquilo, hidroxialcoxi, carboxi, ciano, acilo, alcoxicarbonilo, alquiltio, alquilsulfinilo, alquilsulfonilo, fenoxi, acilamido y aciloxi o combinaciones de los mismos,un grupo carbocíclico parcialmente insaturado con entre 5 y 14 átomos de carbono, que no está sustituido o está sustituido una o más veces por halógeno, alquilo, alcoxi, nitro, ciano, oxo, o combinaciones de los mismos,arilalquenilo con entre 8 y 16 átomos de carbono, donde la porción alquenilo tiene hasta 5 átomos de carbono, ...
CO04034582A 2001-10-16 2004-04-15 Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos CO5570674A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32931401P 2001-10-16 2001-10-16

Publications (1)

Publication Number Publication Date
CO5570674A2 true CO5570674A2 (es) 2005-10-31

Family

ID=23284824

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04034582A CO5570674A2 (es) 2001-10-16 2004-04-15 Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos

Country Status (20)

Country Link
US (3) US7235579B2 (es)
EP (1) EP1435944B1 (es)
JP (2) JP4484515B2 (es)
KR (2) KR20090080573A (es)
CN (1) CN1604776A (es)
AT (1) ATE444065T1 (es)
AU (1) AU2002335015B8 (es)
BR (1) BR0213660A (es)
CA (1) CA2463469A1 (es)
CO (1) CO5570674A2 (es)
DE (1) DE60233884D1 (es)
ES (1) ES2334650T3 (es)
HR (1) HRP20040409A2 (es)
IL (1) IL161317A0 (es)
MX (1) MXPA04003516A (es)
NO (1) NO20042024L (es)
NZ (1) NZ532288A (es)
RU (2) RU2340600C2 (es)
WO (1) WO2003032981A1 (es)
ZA (1) ZA200402856B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
ATE444488T1 (de) * 2000-12-14 2009-10-15 Burnham Inst Non-apoptotische formen des zelltods und verfahren zur modulation
DE60233884D1 (de) 2001-10-16 2009-11-12 Memory Pharmaceutical Corp 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
US20030157053A1 (en) * 2002-02-19 2003-08-21 Sabina Sperandio Modulators of paraptosis and related methods
US7495016B2 (en) 2002-10-21 2009-02-24 Irm Llc Pyrrolidones with anti-HIV activity
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
JP2006523710A (ja) * 2003-04-16 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４インヒビター
JP2006525312A (ja) * 2003-04-28 2006-11-09 アブ サイエンス 脳虚血を治療するためのチロシンキナーゼ阻害剤の使用方法
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
JP2008517066A (ja) * 2004-10-20 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ４阻害剤
ZA200803758B (en) 2005-11-15 2009-08-26 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
CA2635262C (en) * 2005-12-30 2011-08-16 Merck & Co., Inc. 1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors
SG10201407258RA (en) * 2006-05-19 2015-01-29 Dart Neuroscience Cayman Ltd Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
WO2009067607A2 (en) * 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
CA2740610C (en) 2008-10-16 2020-01-07 The Johns Hopkins University Synaptic vesicle protein 2a inhibitors for treating age-related cognitive impairment
WO2010075086A2 (en) * 2008-12-15 2010-07-01 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
EP2443089B1 (en) 2009-06-18 2014-03-05 Concert Pharmaceuticals Inc. Deuterated isoindoline-1,3-dione derivatives as pde4 and tnf-alpha inhibitors
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
WO2016020786A1 (en) 2014-08-06 2016-02-11 Pfizer Inc. Imidazopyridazine compounds
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
TW202146385A (zh) * 2020-04-29 2021-12-16 大陸商廣東東陽光藥業有限公司 取代的吡咯烷類化合物及其在藥物中的應用
CN112479966B (zh) * 2020-12-11 2022-05-17 南京工业大学 一种咯利普兰的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
DE2834114A1 (de) 1978-08-01 1980-02-14 Schering Ag Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung
DE3438839A1 (de) * 1984-10-19 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen Pharmazeutische praeparate
US5128358A (en) 1988-01-19 1992-07-07 Pfizer Inc. Aryl substituted nitrogen heterocyclic antidepressants
DD295358A5 (de) 1989-06-28 1991-10-31 �����@������������������k�� Verfahren zur racemattrennung von 4-aryl-2-oxo-pyrrolidin-3-carbonsaeure-estern
GB9009395D0 (en) 1990-04-26 1990-06-20 Orion Yhtymae Oy Cyclic hydroxamic acids and their use
US5935978A (en) 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
AU2869092A (en) * 1991-10-11 1993-05-03 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
DE69309030T2 (de) 1992-06-15 1997-09-25 Celltech Therapeutics Ltd Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
ATE234270T1 (de) * 1992-12-02 2003-03-15 Pfizer Cathecoldiether als selektive pde iv hemmungsmittel
TW263495B (es) 1992-12-23 1995-11-21 Celltech Ltd
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
JPH07300455A (ja) * 1994-03-08 1995-11-14 Mitsubishi Chem Corp ３−フェニルピロリジン誘導体
JP3696884B2 (ja) 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド ジュウテリウム化による薬物の効能の増強
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO1995028926A1 (en) * 1994-04-21 1995-11-02 Schering Aktiengesellschaft Pde iv inhibitors for treating multiple sclerosis
GB9412383D0 (en) 1994-06-21 1994-08-10 Celltech Ltd Chemical compound
DE19601938A1 (de) 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
JPH1072415A (ja) 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
WO1998058901A1 (fr) 1997-06-24 1998-12-30 Nikken Chemicals Co., Ltd. Derives de la 3-anilino-2-cycloalcenone
JP3085249B2 (ja) 1997-07-09 2000-09-04 松下電器産業株式会社 ホットプレート
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6372777B1 (en) 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6555572B2 (en) 2000-03-16 2003-04-29 Inflazyme Pharmaceuticals Ltd. Benzylated PDE4 inhibitors
EP1343528A2 (en) 2000-11-02 2003-09-17 Research Foundation of City University of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
DE60233884D1 (de) 2001-10-16 2009-11-12 Memory Pharmaceutical Corp 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
JP2006523710A (ja) 2003-04-16 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４インヒビター

Also Published As

Publication number Publication date
KR20050037404A (ko) 2005-04-21
CA2463469A1 (en) 2003-04-24
EP1435944A1 (en) 2004-07-14
CN1604776A (zh) 2005-04-06
ES2334650T3 (es) 2010-03-15
ZA200402856B (en) 2005-01-25
HRP20040409A2 (en) 2005-06-30
ATE444065T1 (de) 2009-10-15
KR100951218B1 (ko) 2010-04-05
IL161317A0 (en) 2004-09-27
AU2002335015B2 (en) 2006-11-02
DE60233884D1 (de) 2009-11-12
NO20042024L (no) 2004-05-14
US7235579B2 (en) 2007-06-26
US20090176799A1 (en) 2009-07-09
EP1435944B1 (en) 2009-09-30
JP2009286797A (ja) 2009-12-10
RU2340600C2 (ru) 2008-12-10
KR20090080573A (ko) 2009-07-24
RU2008123376A (ru) 2009-12-27
US20030139406A1 (en) 2003-07-24
BR0213660A (pt) 2004-08-24
RU2004115333A (ru) 2005-10-27
WO2003032981A1 (en) 2003-04-24
MXPA04003516A (es) 2004-07-23
JP4484515B2 (ja) 2010-06-16
JP2005508961A (ja) 2005-04-07
US20050272803A1 (en) 2005-12-08
NZ532288A (en) 2005-12-23
AU2002335015B8 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
CO5570674A2 (es) Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
SG169900A1 (en) 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
NO20050870L (no) Fosfodiesterase 4-inhibitorer, inkludert N-substituerte anilin- og difenylaminanaloger
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
NO20082346L (no) Hydrazonderivater og anvendelser derav
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
PA8552501A1 (es) 1-alquil o 1-cicloalquil-triazolo[4,3-a]quinazolin-5-onas como inhibidoras de fosfodiesterasa
NO20062894L (no) 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
ATE368666T1 (de) Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
BRPI0510865A (pt) inibidores seletivos de butirilcolinesterase: composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto
ATE279113T1 (de) Hypoxanthin- und thiohypxanthin-verbindungen
UY27411A1 (es) 1-alquil o 1-cicloalquil-triazolo (4, 3-a) quinazolin-5-onas como inhibidoras de fosfodiesterasa.

Legal Events

Date Code Title Description
FC Application refused